CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 152 enrolled
Drug / intervention
Olanzapine +1 moredrug
Likely dose
Olanzapine 2.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01170117
NCT01170117N/ACompleted
CompareCT.gov

Olanzapine vs Placebo for Outpatients With Anorexia Nervosa

New York State Psychiatric Institute·interventional·Posted Jul 27, 2010·Updated Jun 29, 2018

In Brief

A clinical study evaluating Olanzapine and Placebo for Anorexia Nervosa. Completed, enrolled 152 participants across 5 sites in 2 countries.

Detailed Summary

Anorexia Nervosa (AN) is a serious illness associated with substantial morbidity and mortality. Weight restoration is a treatment priority, and better treatments are needed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnorexia Nervosa
CountriesCanada, United States
CollaboratorsNational Institute of Mental Health (NIMH), Weill Medical College of Cornell University, University of Pittsburgh, Johns Hopkins University, University of Toronto

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 27, 2010
Enrollment StartAug 1, 2010
Primary CompletionJun 1, 2016
Study CompletionJun 1, 2017
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 15.9 years ago

Interventions

Olanzapinedrug

Dosing of olanzapine will begin at 2.5 mg and will be titrated to a maximum dose of 10 mg. The target dose of 10 mg of olanzapine was selected because published data from studies that used this dose indicated that it was helpful to patients.

Placebodrug

Control Group will receive placebo pill